Association of patient characteristics and insurance type with anti‐obesity medications prescribing and fills

Abstract

AbstractAimTo characterize factors associated with the receipt of anti‐obesity medication (AOM) prescription and fill.Materials and MethodsThis retrospective cohort study used electronic health records from 1 January 2015 to 30 June 2023, in a large health system in Ohio and Florida. Adults with a body mass index ≥30 kg/m2 who attended ≥1 weight‐management programme or had an initial AOM prescription between 1 July 2015 and 31 December 2022, were included. The main measures were a prescription for an AOM (naltrexone‐bupropion, orlistat, phentermine‐topiramate, liraglutide 3.0 mg and semaglutide 2.4 mg) and an AOM fill during the study follow‐up.ResultsWe identified 50 678 adults, with a mean body mass index of 38 ± 8 kg/m2 and follow‐up of 4.7 ± 2.4 years. Only 8.0% of the cohort had AOM prescriptions and 4.4% had filled prescriptions. In the multivariable analyses, being a man, Black, Hispanic and other race/ethnicity (vs. White), Medicaid, traditional Medicare, Medicare Advantage, self‐pay and other insurance types (vs. private insurance) and fourth quartile of the area deprivation index (vs. first quartile) were associated with lower odds of a new prescription. Hispanic ethnicity, being a man, Medicaid, traditional Medicare and Medicare Advantage insurance types, liraglutide and orlistat (vs. naltrexone‐buproprion) were associated with lower odds of AOM fill, while phentermine‐topiramate was associated with higher odds. Among privately insured individuals, the insurance carrier was associated with both the odds of AOM prescription and fill.ConclusionsSignificant disparities exist in access to AOM both at the prescribing stage and getting the prescription filled based on patient characteristics and insurance type.